Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Anaesth Crit Care Pain Med ; 38(1): 35-39, 2019 02.
Article in English | MEDLINE | ID: mdl-29033356

ABSTRACT

INTRODUCTION: Analgesia Nociception Index (ANI) has been proposed for the evaluation of the nociception-antinociception balance in the perioperative period. In obese patients, where the management of analgesia may be rendered difficult by pharmacological changes, we hypothesised that the monitoring of analgesia with ANI would reduce intraoperative opioid consumption during bariatric surgery. METHODS: This monocentric, observational, unmatched case-control study aimed to compare perioperative data from obese subjects (body mass index ≥35kgm-2) during bariatric surgery with or without the use of ANI monitoring (ANI+ group versus ANI- group). Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment in the ANI- group or to the ANI value in the ANI+ group. The primary outcome was the mean hourly intraoperative sufentanil requirement. Secondary outcomes included the need for postoperative morphine titration, incidence of nausea and vomiting, respiratory distress and pain scores in the first 24hours. RESULTS: Between December 2013 and September 2016, 60 obese patients (i.e. 30 per group) were included. The mean hourly consumption of sufentanil was significantly lower in the ANI+ group (0.15±0.05µgkg-1h-1 versus 0.17±0.05µgkg-1h-1, P=0.038). We found no difference between groups regarding the incidence of nausea and vomiting, acute respiratory distress, the need for postoperative morphine titration, or pain scores in the first 24 postoperative hours. CONCLUSION: The use of ANI monitoring might reduce intraoperative consumption of sufentanil during bariatric surgery but does not appear to be accompanied by a reduction in its side effects.


Subject(s)
Analgesia/methods , Analgesics, Opioid/administration & dosage , Bariatric Surgery , Nociception , Obesity , Sufentanil/administration & dosage , Adult , Analgesics, Opioid/adverse effects , Body Mass Index , Case-Control Studies , Female , Humans , Male , Middle Aged , Morphine/administration & dosage , Nausea/chemically induced , Obesity/physiopathology , Obesity/surgery , Pain Measurement , Respiratory Distress Syndrome/chemically induced , Sufentanil/adverse effects , Time Factors , Vomiting/chemically induced
2.
Liver Transpl ; 22(4): 516-26, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26919265

ABSTRACT

The aim of this study was to collect data from patients who underwent liver transplantation (LT) for adenomatosis; to analyze the symptoms, the characteristics of the disease, and the recipient outcomes; and to better define the role of LT in this rare indication. This retrospective multicenter study, based on data from the European Liver Transplant Registry, encompassed patients who underwent LT for adenomatosis between January 1, 1986, and July 15, 2013, in Europe. Patients with glycogen storage disease (GSD) type IA were not excluded. This study included 49 patients. Sixteen patients had GSD, and 7 had liver vascular abnormalities. The main indications for transplantation were either a suspicion of hepatocellular carcinoma (HCC; 15 patients) or a histologically proven HCC (16 patients), but only 17 had actual malignant transformation (MT) of adenomas. GSD status was similar for the 2 groups, except for age and the presence of HCC on explants (P = 0.030). Three patients with HCC on explant developed recurrence after transplantation. We obtained and studied the pathomolecular characteristics for 23 patients. In conclusion, LT should remain an extremely rare treatment for adenomatosis. Indications for transplantation primarily concern the MT of adenomas. The decision should rely on morphological data and histological evidence of MT. Additional indications should be discussed on a case-by-case basis. In this report, we propose a simplified approach to this decision-making process.


Subject(s)
Adenoma, Liver Cell/surgery , Carcinoma, Hepatocellular/surgery , Liver Neoplasms/surgery , Liver Transplantation/statistics & numerical data , Rare Diseases/surgery , Adenoma, Liver Cell/pathology , Adult , Carcinoma, Hepatocellular/pathology , Clinical Decision-Making/methods , Cohort Studies , Europe/epidemiology , Female , Glycogen Storage Disease Type I/surgery , Humans , Liver Neoplasms/pathology , Male , Registries/statistics & numerical data , Retrospective Studies , Treatment Outcome
3.
World J Surg ; 38(11): 2791-6, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25015726

ABSTRACT

BACKGROUND: Because of the lack of published data and the relative rarity of lateral incisional hernias (LIHs), especially after renal transplantation, mesh repair of LIH remains a challenge for surgeons. The aim of the present study was to evaluate the outcomes of LIH treated by mesh repair after renal transplantation. METHODS: All consecutive patients who had undergone LIH mesh repair after renal transplantation were compared with patients who had undergone LIH mesh repair without renal transplantation. Demographic data, incisional hernia characteristics, operative data, and postoperative outcomes were prospectively recorded. Early complications and recurrence rates were evaluated. RESULTS: Altogether, 112 patients were treated for LIH with mesh repair. Among these patients, 61 (54.4 %) underwent LIH after renal transplantation. The early complications were similar for the patients with and without renal transplantation (24.5 vs. 23.5 %, respectively; p = 0.896). The recurrence rates also were similar for the patients with and without renal transplantation (9.8 vs. 9.8 %, respectively; p = 1). CONCLUSIONS: Mesh graft repair is feasible in patients with LIH after renal transplantation. Postoperative complications and recurrences were not more frequent in renal transplantation patients than in those without renal transplantation.


Subject(s)
Hernia, Ventral/surgery , Kidney Transplantation , Postoperative Complications/surgery , Surgical Mesh , Adult , Body Mass Index , Female , Humans , Male , Middle Aged , Recurrence , Surgical Mesh/adverse effects , Wound Healing
4.
Surgery ; 155(1): 5-12, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24084595

ABSTRACT

AIM: To report the results of complete cytoreductive surgery (CCRS) of peritoneal metastases from neuroendocrine tumor (NET) and to compare patients treated with or without hyperthermic intraperitoneal chemotherapy (HIPEC). BACKGROUND: Aggressive management of peritoneal metastases from NET (in most of the cases associated with other types of metastases) has not been addressed in the literature, but these metastases affect overall survival. PATIENTS AND METHODS: From 1994 to 2012, 41 patients underwent CCRS, with HIPEC (n = 28) from 1994 to 2007 but without HIPEC (n = 13) from 2008 to 2012. Liver metastases were treated during the same operative procedure in 66% of the patients. RESULTS: Mortality was 2% and morbidity 56%. Overall survival at 5 and 10 years was 69% and 52%, respectively, and disease-free survival at 5 and 10 years was 17% and 6%, respectively. At 5 years, peritoneal metastases and liver metastases recurred in 47% and in 66% of cases, respectively. Overall survival was not different between patients treated with or without HIPEC, but disease-free survival was greater in the HIPEC group (P = .018), mainly because of fewer lung and bone metastases. CONCLUSION: CCRS of peritoneal metastases from a NET is feasible in most of the patients and seems to increase survival rates. We were unable to determine whether adding HIPEC had a positive or a negative impact.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Neuroendocrine/surgery , Hyperthermia, Induced , Peritoneal Neoplasms/surgery , Adult , Aged , Carcinoma, Neuroendocrine/drug therapy , Carcinoma, Neuroendocrine/secondary , Female , France/epidemiology , Humans , Infusions, Parenteral , Male , Middle Aged , Neoplasm Metastasis , Perioperative Period/statistics & numerical data , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/secondary , Retrospective Studies , Survival Analysis
5.
Pharmacoepidemiol Drug Saf ; 18(12): 1176-84, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19757412

ABSTRACT

PURPOSE: Data mining on electronic health records (EHRs) has emerged as a promising complementary method for post-marketing drug safety surveillance. The EU-ADR project, funded by the European Commission, is developing techniques that allow mining of EHRs for adverse drug events across different countries in Europe. Since mining on all possible events was considered to unduly increase the number of spurious signals, we wanted to create a ranked list of high-priority events. METHODS: Scientific literature, medical textbooks, and websites of regulatory agencies were reviewed to create a preliminary list of events that are deemed important in pharmacovigilance. Two teams of pharmacovigilance experts independently rated each event on five criteria: 'trigger for drug withdrawal', 'trigger for black box warning', 'leading to emergency department visit or hospital admission', 'probability of event to be drug-related', and 'likelihood of death'. In case of disagreement, a consensus score was obtained. Ordinal scales between 0 and 3 were used for rating the criteria, and an overall score was computed to rank the events. RESULTS: An initial list comprising 23 adverse events was identified. After rating all the events and calculation of overall scores, a ranked list was established. The top-ranking events were: cutaneous bullous eruptions, acute renal failure, anaphylactic shock, acute myocardial infarction, and rhabdomyolysis. CONCLUSIONS: A ranked list of 23 adverse drug events judged as important in pharmacovigilance was created to permit focused data mining. The list will need to be updated periodically as knowledge on drug safety evolves and new issues in drug safety arise.


Subject(s)
Adverse Drug Reaction Reporting Systems/organization & administration , Data Mining/methods , Drug Monitoring/methods , Drug-Related Side Effects and Adverse Reactions , Electronic Health Records , Databases, Factual , Europe , Humans , Risk Assessment
SELECTION OF CITATIONS
SEARCH DETAIL
...